TP方案在三阴性乳腺癌新辅助化疗中的疗效及预后分析  

Effect and prognosis of docetaxel and carboplatin in neoadjuvant chemotherapy for triple negative breast cancer

作　　者：郭书坤 徐艳蕾 袁超 李方志 郑仪 Guo Shukun;Xu Yanlei;Yuan Chao;Li Fangzhi;Zheng Yi(The Second People's Hospital of Dezhou,Shandong Dezhou 253000,China)

机构地区：[1]德州市第二人民医院,山东德州253000

出　　处：《现代肿瘤医学》2020年第11期1874-1877,共4页Journal of Modern Oncology

摘　　要：目的:探讨TP方案在三阴性乳腺癌新辅助化疗中的疗效,分析新辅助化疗疗效对预后的影响。方法:收集2011年08月至2015年06月德州市第二人民医院乳腺科收治的三阴性乳腺癌患者98例,所有患者均排除远处转移,随机分为研究组50例(给予TP方案新辅助化疗)和对照组48例(给予TAC方案新辅助化疗),观察其疗效,并对患者进行随访,统计其3年的无病生存率及总生存率。结果:研究组总有效率为84.0%(42/50),完全缓解率为36.0%(18/50),对照组总有效率为77.1%(37/48),完全缓解率为14.6%(7/48),总有效率无统计学差异(P=0.837),完全缓解率有统计学差异(P=0.037)。新辅助化疗有效组3年DFS为96.2%(76/79),3年OS为100.0%(79/79),新辅助化疗无效组3年DFS为63.2%(12/19),3年OS为94.7%(18/19),3年DFS有统计学差异(P<0.001),3年OS无统计学差异(P=0.194)。结论:TP方案较TAC方案在三阴性乳腺癌新辅助化疗中有较好的完全缓解率,总有效率无差异,新辅助化疗有效性可转化为较好的预后。Objective:To investigate the effect of docetaxel and carboplatin in neoadjuvant chemotherapy of triple negative breast cancer(TNBC)and analyze the effect of neoadjuvant chemotherapy on prognosis.Methods:98 cases of TNBC were collected from August 2011 to June 2015 in the breast cancer department of the Second People’s Hospital of Dezhou.All patients were excluded from distant metastasis and randomly divided into research group and control group.50 cases of the research group were given the neoadjuvant chemotherapy of TP.In the control group,48 patients were given neoadjuvant chemotherapy of TAC.The efficacy was observed and the patients were followed up.The disease-free survival rate and overall survival rate for 3 years were observed.Results:In research group,total efficiency rate was 84.0%(42/50),and complete remission rate was 36.0%(18/50).In control group,total efficiency rate was 77.1%(37/48),and complete remission rate was 14.6%(7/48).There was no statistical difference in total efficiency rate(P=0.837),and there was a statistical difference in the complete remission rate(P=0.037).3 years DFS of the effective group after neoadyuvant chemotherapy was 96.2%(76/79),and 3 years OS was 100.0%(79/79).3 years DFS of invalid group after neoadyuvant chemotherapy was 63.2%(12/19),and 3 years OS was 94.7%(18/19).3 years DFS had statistical differences(P<0.001).There was no statistical difference in 3 years OS(P=0.194).Conclusion:TP regimen has a better complete remission rate than TAC regimen in neoadjuvant chemotherapy for TNBC.There is no difference in overall survival rate,and the effectiveness of neoadjuvant chemotherapy can be converted into a better prognosis.

关 键 词：TP方案 三阴性乳腺癌 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤]